Disclosed is the use of a sex steroid precursor selected from the group consisting of dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androst-5-ene-3beta,17beta-diol, and 4-androsten-3,17-dione, optionally combined with a Selective Estrogen Receptor Modulator (Acolbifene), in the manufacture of a medicament for treating or reducing the likelihood of acquiring vaginal diseases or problems selected from urinary incontinence, vaginal atrophy, atrophic vaginitis, vaginal dryness, dyspareunia and sexual dysfunction in postmenopausal women, wherein said medicament is formulated for intravaginal administration of said sex steroid precursor at a therapeutic amount of 13 mg per day or less. Further disclosed is a pharmaceutical composition for intravaginal administration comprising a sex steroid precursor selected from dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androst-5-ene-3beta,17beta-diol, and 4-androsten-3,17-dione and further comprising a pharmaceutically acceptable excipient, diluent or carrier. Also disclosed is a vaginal suppository comprising dehydroepiandrosterone, dehydroepiandrosterone-sulfate, androst-5-ene-3beta,17beta-diol, and 4-androsten-3,17-dione and an excipient comprising saturated fatty acid asters or Witepsol H-15.
